StemCells Profile

  
0.3735
USD 0.0068  1.79%
10 Days Price Trend

StemCells Market Sensitivity

As returns on market increase, returns on owning StemCells are expected to decrease by larger amounts. On the other hand, during market turmoil, StemCells is expected to significantly outperform it.
One Month Beta |Analyze StemCells Inc Demand Trend
Check current 30 days StemCells correlation with market (NYSE)
β = -1.9505
StemCells Large Negative BetaStemCells Inc Beta Legend

Selected StemCells Inc Income Statement Over Time

Cost of Revenue    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

StemCells Against Markets

StemCells Leadership

Martin McGlynn CEO, Director, Member of Strategic Transactions Committee, CEO of Stemcells California Inc and President of Stemcells California Inc
John Schwartz Independent Chairman of the Board, Ph.D
More Executives

StemCells Diversification Suggestion

Use StemCells to protect against small markets fluctuations. The stock experiences somewhat bearish sentiment, but market may correct it shortly. Check odds of StemCells to be traded at $0.3623 in 30 days

StemCells Daily Price Distribution

The median price of StemCells for the period between Thu, Jun 30, 2016 and Sat, Jul 30, 2016 is 0.3943 with a coefficient of variation of 5.35. The daily time series for the period is distributed with a sample standard deviation of 0.02, arithmetic mean of 0.39, and mean deviation of 0.02. The Stock received some media coverage during the period.

StemCells Summary

StemCells Inc (STEM) is traded on Nasdaq Capital Markets in USA. It is located in CALIFORNIA, U.S.A and employs 74 people. StemCells is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with current market capitalization of 4.21 M. StemCells Inc conducts business under Healthcare sector and is part of Biotechnology industry. This company has 11.7 M outstanding shares of which 459.17 K shares are at this time shorted by private and institutional investors with about 0.68 trading days to cover. STEMCELLS INC currently holds about 8.67 M in cash with (31.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.74 which can makes it an attractive takeover target, given it will continue generating positive cash flow.
StemCells Inc. a biopharmaceutical company engages in the research development and commercialization of cellbased therapeutics and related technologies. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameStemCells Inc
InstrumentUSA Stock
ExchangeNasdaq Capital Markets
CUSIP85857R204
SectorHealthcare
IndustryBiotechnology
BenchmarkNYSE
Websitehttp://www.stemcellsinc.com
Contact Number510 456 4000
LocationCALIFORNIA, U.S.A
Analyst Consensus
Macroaxis Advice
CurrencyUSD - US Dollar
Directors
StemCells Corporate Directors
Irving Weissman Director
Eric Bjerkholt Independent Director
R Greer Independent Director
StemCells Alerts
Equity Alerts and Improvement Suggestions
StemCells Inc generates negative expected return over the last 30 days
StemCells Inc has high historical volatility and very poor performance
StemCells Inc has some characteristics of a very speculative penny stock
StemCells Inc has high likelihood to experience some financial distress in the next 2 years
The company reported previous year revenue of 119.05 K. Net Loss for the year was (36.63 M) with profit before overhead, payroll, taxes, and interest of 116.89 K.
STEMCELLS INC currently holds about 8.67 M in cash with (31.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.74 which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Latest headline from sharemarketupdates.com: HC Stocks Updates Idera Pharmaceuticals Inc StemCells Inc ...
Corporate Filings
StemCells Corporate Filings
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Regulation FD Disclosure
Other Events. Cost Associated with Exit or Disposal Activities
Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year
Company Reports
StemCells Corporate Reports
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance
Opportunities
Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  
Earnings
StemCells Earnings Estimates
StemCells Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  
Research Report
Get StemCells research report
Get StemCells research report. Reports are available in pdf format and contain fundamental information about the equity. Click Research Report to view
Pair Trading
StemCells Pair Trading Analysis
Correlation analysis and pair trading evaluation for StemCells and Amgen Inc. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation